Research programme: TNF receptor antagonists - ProSkelia
Latest Information Update: 23 May 2007
At a glance
- Originator ProSkelia
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bone resorption
Most Recent Events
- 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
- 05 May 2003 Preclinical trials in Bone resorption in Europe (unspecified route)